

## **Approaches for capture of histidine-tagged proteins in Biacore systems**

**Intellectual Property Notice:** The Biopharma business of GE Healthcare was acquired by Danaher on 31 March 2020 and now operates under the Cytiva™ brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

#### **cytiv[a.com](http://cytiva.com)**

GE and the GE Monogram are trademarks of General Electric Company. Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. All other third-party trademarks are the property of their respective owners. © 2020 Cytiva

All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.

For local office contact information, visit [cytiva.com/contact](http://cytiva.com/contact)

# Approaches for capture of histidinetagged proteins in Biacore™ systems

**Capture of histidine-tagged proteins for interaction analysis in Biacore systems can be achieved either via nickel (Ni2+) chelation of nitrilotriacetic acid (NTA) or by covalently coupling an anti-histidine antibody to the sensor surface. Both alternatives give high binding capacities and allow simple regeneration and reuse for multiple cycles. GE Healthcare provides dedicated products supporting both approaches, offering easy set-up and use in Biacore systems.**

**The features of the two approaches are discussed here, and guidelines for working with histidine-tagged proteins in Biacore assays are provided.** 

## **Introduction**

One of the tags most widely used to facilitate purification of recombinant proteins is the histidine tag, which typically consists of six consecutive histidine residues added to the C- or N-terminus of the protein.

Attachment of proteins to sensor surfaces via capture of a histidine tag is attractive since physiological conditions can be used during the capture procedure. Another advantage is that histidine capture generates a uniform structural orientation of the ligand. Two capture approaches are frequently used: Capture on nickel-chelated NTA groups, and capture by immobilized anti-histidine antibodies. In both cases, a generic regeneration method can be applied for all types of proteins.

In this Application note tips and hints for working with histidine-tagged proteins in Biacore systems are described.

## **Materials and methods**

All experiments were performed using Biacore T100 or Biacore 4000. The following buffers were used: HBS-P+ or PBS-P+, with 50 µM EDTA added, for Sensor Chip NTA, and HBS-EP+ for His Capture Kit.



**Fig 1.** Sensor Chip NTA is used for the study of molecular interactions between histidine-tagged proteins immobilized on the chip and numerous analytes.

## *Capture and analysis using Sensor Chip NTA*

Sensor Chip NTA was activated by injecting a solution of Ni<sup>2+</sup> ions followed by capture of the histidine-tagged protein. The analyte solution was injected and the binding signal(s) monitored. The NTA surface was then regenerated by a pulse of EDTA. Running conditions for the use of Sensor Chip NTA in this study are listed in Table 1.

**Table 1.** Running conditions for kinetic characterization of analytes binding to their respective ligands integrin  $\alpha$ 1 $\beta$ 9, MBP, and cystatin B captured on Sensor Chip NTA



\* Only at the beginning of each experiment



#### *Capture using anti-histidine antibody*

The anti-histidine antibody provided in His Capture Kit was diluted to 50 µg/ml in the immobilization buffer included in the kit and covalently coupled to Sensor Chip CM5 by standard amine coupling to a level of approximately 12 000 RU. Parameters for immobilization of the antibody and subsequent analysis of the histidine-tagged proteins are listed in Tables 2 and 3.

#### **Table 2.** Immobilization conditions for anti-histidine antibody



**Table 3.** Running conditions for kinetic characterization of analytes binding to their respective ligands integrin integrin α1β9, MBP, and cystatin B captured on an anti-histidine antibody surface



#### *Use of reference surface*

When working with capture to anti-histidine antibodies, the reference surface should be immobilized with anti-histidine antibody using settings identical to those used for the active surface.

When working with Sensor Chip NTA, the reference surface should be a non-activated flow cell/detection spot that has not been subjected to Ni<sup>2+</sup> ions. For a surface loaded with Ni<sup>2+</sup> ions, but without ligand, there is a risk of nonspecific binding from complex sample matrices at a level that does not match the active surface.

As the remaining amount of unoccupied nickel-chelated groups on Sensor Chip NTA may increase the probability for analyte binding to the active surface, it is recommended to start work on Sensor Chip NTA with a control experiment checking for unwanted analyte binding on an activated surface.

## **Results and discussion** *Capture stability*

Capture stability varies between histidine-tagged proteins, largely depending on the nature of the protein itself and on the microenvironment of the tag in particular. Other factors that influence the stability of the capture are type of capturing surface and amount of captured protein. In order to increase stability, capture levels should generally be kept as low as possible.

Three histidine-tagged proteins (Integrin α9β1, M<sub>r</sub> 200 000; maltose binding protein [MBP], M<sub>,</sub> 43 000; cystatin B, M<sub>.</sub> 11 000) were captured on both Sensor Chip NTA and an anti-his antibody surface. The sensorgrams are shown in Figure 2. Integrin α9β1 (Fig 2A) and MBP (Fig 2B) do not give stable baselines with either of the capture approaches. Cystatin B, on the other hand, gives a stable baseline with Sensor Chip NTA while capture with anti-histidine antibody is less stable (Fig 2C). These are examples where assay development is necessary to obtain a stable binding of the histidine-tagged protein.



**Fig 2.** Capture of histidine-tagged proteins on Sensor Chip NTA (green curve) and anti-his antibody surface (red curve) in Biacore T100. **A)** Integrin α9β1 1.25 µg/ml; **B)** MBP 20 µg/ml; **C)** cystatin B 0.6 µg/ml.

As mentioned, there are several ways to increase the binding stability of captured histidine-tagged proteins. An efficient and simple approach is to decrease the protein load. This provides a larger number of unoccupied binding sites on the surface which, in turn, increases the probability for rebinding of dissociating proteins.

A lower capture level can be obtained by adjustment of the protein concentration or by a shorter contact time. Examples of injections of varying concentrations of histidine-tagged proteins over Sensor Chip NTA and antihistidine antibody are shown in Figures 3 and 4.

In all these examples, it is clear that the stability increases with a lower capturing level. In most cases, it is easy to achieve a level with excellent stability.

At 50 nM, cystatin B dissociates fairly rapidly from the surface, 0.35 RU/s (Fig 4B, purple curve). When the concentration is lowered the dissociation rate is reduced, and at 6.3 nM (light blue curve), the dissociation of protein from the surface is less than 0.01 RU/s, which is sufficient for high quality kinetic studies.

For some applications, however, a compromise between a capture level high enough to give a good analyte response and sufficient stability must be made.



**Fig 3.** Concentration series for capture of histidine-tagged proteins on Sensor Chip NTA. **A)** Green Fluorescent Protein (GFP, M<sub>,</sub> 27 000, 0.8 to 6.4 µg/ml); **B)** PARP10 (M<sub>r</sub> 25 000, 0.8 to 6.4 µg/ml).

**Fig 4.** Concentration series for capture of histidine-tagged proteins over an anti-his surface: **A)** PARP10 (0.8 to 6.4 µg/ml); **B)** cystatin B (3 to 50 nM).

0.8 µg/ml

12.5 nM

3.1 nM

6.3 nM

25 nM

50 nM

1.6 µg/ml

3.2 µg/ml

6.4 µg/ml

High-stability capture is especially critical when performing single-cycle kinetics where each analysis is performed in one long sample cycle. Kinetic characterization of the interaction between cystatin B and papain (M<sub>,</sub> 23 400) was determined using the single-cycle kinetics approach at a capture level of 30 RU, and a protein concentration of 0.125 to 2 nM on the anti-histidine surface. The results are summarized in Figure 5. The data was fitted to a 1:1 binding model with high accuracy, as demonstrated by the statistical parameters such as the reported Chi<sup>2</sup> value (0.05 RU2 ). The anti-histidine capture approach thus enabled a stable capture allowing confident generation of kinetic values.





#### *Covalent coupling on Sensor Chip NTA*

An alternative way of increasing capture stability on Sensor Chip NTA is to perform an amine coupling of the captured ligand. The NTA groups are first chelated with nickel ions and after activation with EDC/NHS, the ligand is injected and covalently bound. The nickel ions are then removed with 350 mM EDTA. This immobilization method does not require preconcentration and the ligand can be immobilized out of a crude sample. With a covalently coupled ligand, regeneration conditions must be optimized for each specific protein/analyte interaction.

Cystatin B was diluted to 6 nM in HBS-P+ buffer and immobilized on Sensor Chip NTA by the combined capture and amine coupling method. Single-cycle kinetic analysis was performed with papain as analyte (Fig 6). The data was fitted to a 1:1 binding model and the results correlated well with the kinetic constants obtained with regular capture to an anti-histidine surface (Fig 5).



**Fig 6.** Kinetic characterization of papain (0.125 to 2 nM) binding to cystatin B covalently coupled to Sensor Chip NTA.

#### *Nonspecific binding*

Approximately 2% of all residues in a protein are histidine. This means that, in addition to the specific tag, NTA and anti-histidine antibodies might to some extent bind to naturally occurring histidine in the proteins. Native proteins containing histidine without a histidine tag might therefore generate a response. Nonspecific binding should always be assessed in relation to the specific response to evaluate whether it will impact the results. If one of the histidinecapture approaches gives unsatisfactory results with respect to nonspecific binding, the other should be tested since the nature of nonspecific binding might differ between the two approaches.

#### *Tag length and composition affect capture stability*

Investigations of isolated hexahistidine tags suggest that they have high affinities with a  $K_{\rm o}$  in the nanomolar range, and that no further improvements are seen with extended histidine tags (1). When tags are attached to proteins, however, the number of tags and the length of tags can affect capture efficiency. Currently, double histidine tags are thought to provide the best means of improving affinity on an NTA surface. Lengthening the tag does not necessarily lead to enhanced affinity as triple tags have been shown to aggregate.

In a publication from the University of York (2), capture of the protein SiaP, equipped with either of three different sets of histidine tags (hexahistidine, decahistidine, and a double tag containing both a hexahistidine and a decahistidine) immobilized on Sensor Chip NTA was studied to assess the trade-off between inadequate stability of immobilized protein at high RU levels and insufficient analyte binding response at low RUs. The results show that SiaP tagged with decahistidine was more stably captured on Sensor Chip NTA than SiaP tagged with hexahistidine, and that the best results were obtained with the double histidine tag (Fig 7).



**Fig 7.** Stability of histidine-tagged SiaP on Sensor Chip NTA: **A)** hexa, **B)** deca, and **C)** double histidine-tagged protein immobilized on Sensor Chip NTA at three concentrations. Reprinted with permission from Analytical Chemistry, © 2011 American Chemical Society.

The hexa-spacer-deca histidine tag, introduced by Fischer *et al.* (3) appears to be an improved construct amongst other double histidine tags documented in literature. The long-term performance of the construct was tested in a Biacore system. Buffer was run over the surface for two days and the average baseline drift was only 2 RU/min, which is sufficiently low to be corrected for within a smallmolecule binding experiment.

In order to minimize a possible negative effect on the function of the protein, it is advisable to use the smallest number of histidine residues required for efficient purification. In general, a hexahistidine tag is an appropriate choice for a first trial when incorporating a polyhistidine tag into a protein.

The final choice of construct is subject to availability of different versions of the protein and the application it will be used for; short-term or long-term screening of weakly or tightly binding analytes.

#### **Conclusions**

Efficient capture of histidine-tagged proteins on Biacore sensor surfaces can be performed using either His Capture Kit or Sensor Chip NTA. Both alternatives give good binding stability and low nonspecific binding, and the choice is dependent on the application. For studies of low-molecular weight analytes, though, Sensor Chip NTA is the first choice. Capture capacity is high and if stability is an issue, the captured ligand can be covalently coupled. This is often an advantageous alternative since regeneration is rarely required for small molecules.

## **Acknowledgements**

Doctor Marcus Fischer at the University of York is acknowledged for contributing valuable knowledge and data regarding studies of histidine tags in Biacore systems. PARP10 was kindly provided by Johan Weigelt at SGC, Karolinska Institute, Stockholm, Sweden.

Cystatin B and papain were kindly provided by Prof. Ingemar Björk's group at the Swedish University of Agricultural Sciences, Sweden.

## **References**

- 1. Knecht, S. *et al.* Oligohis-tags: mechanisms of binding to Ni2+-NTA surfaces. *J. Mol. Recognit.* **22** 270–279 (2009).
- 2. Khan, F. *et al.* Double-hexahistidine tag with high-affinity binding for protein immobilization, purification, and detection on Ni-nitrilotriacetic acid surfaces. *Anal. Chem.* **78** 3072–3079 (2006).
- 3. Fischer M. *et al.* Comparative assessment of different histidine-tags for immobilization of protein onto surface plasmon resonance sensorchips. *Anal. Chem.* **83** 1800–1807 (2011).

## **Ordering information**



\* includes anti-histidine antibody and immobilization buffer for 10 immobilizations and regeneration solution for 1000 regenerations.

 $<sup>†</sup>$  includes Ni<sup>2+</sup> solution and regeneration solution for 1200 injections.</sup>



For local office contact information, visit **www.gelifesciences.com/contact**

www.gelifesciences.com/biacore

GE Healthcare Bio-Sciences AB Björkgatan 30 751 84 Uppsala Sweden



GE, imagination at work and GE monogram are trademarks of General Electric Company.

Biacore is a trademark of GE Healthcare companies.

© 2011 General Electric Company — All rights reserved. First published Oct. 2011

All goods and services are sold subject to the terms and conditions of<br>sale of the company within GE Healthcare which supplies them. A copy<br>of these terms and conditions is available on request. Contact your<br>local GE Healt

GE Healthcare UK Limited Amersham Place Little Chalfont Buckinghamshire, HP7 9NA UK

GE Healthcare Europe, GmbH Munzinger Strasse 5 D-79111 Freiburg Germany

GE Healthcare Bio-Sciences Corp. 800 Centennial Avenue, P.O. Box 1327 Piscataway, NJ 08855-1327 USA

GE Healthcare Japan Corporation Sanken Bldg., 3-25-1, Hyakunincho Shinjuku-ku, Tokyo 169-0073 Japan